

Additional Supporting References and Supporting Appendices

72. Starzl TE. The Puzzle People: Memoirs of a Transplant Surgeon. University of Pittsburgh Press. Pittsburgh, PA. 1992. pp: 1-368
73. Starzl TE, Magoun HW. Organization of the diffuse thalamic projection system. *J Neurophysiol* 1951;14:133-146.
74. Starzl TE, Taylor CW, Magoun HW. Ascending conduction in reticular activating system, with special reference to the diencephalon. *J Neurophysiol* 1951;14:461-477.
75. Starzl TE, Taylor CW, Magoun HW. Collateral afferent excitation of reticular formation of brain stem. *J Neurophysiol* 1951;14:479-496.
76. Starzl TE, Whitlock DG. Diffuse thalamic projection system in monkey. *J Neurophysiol* 1952;15:449-468.
77. Starzl TE, Niemer WT, Dell M, Forgrave PR. Cortical and subcortical electrical activity in experimental seizures induced by metrazol. *J Neuropathol Exp Neurol* 1953;12:262-276.
78. Starzl TE, Gaertner RA, Webb RC Jr. The effects of repetitive electric cardiac stimulation in dogs with normal hearts, complete heart block and experimental cardiac arrest. *Circulation* 1955;11:952-962.
79. Starzl TE, Gaertner RA, Baker RR. Acute complete heart block in dogs. *Circulation* 1955;12:82-89.
80. Starzl TE, Gaertner RA. Chronic heart block in dogs. A method for producing experimental heart failure. *Circulation* 1955;12:259-270.
81. Mirsky IA. The role of insulinase and insulinase inhibitors. *Metabolism* 1956;5:138.
82. Meyer WH Jr, Starzl TE. The reverse portacaval shunt. *Surgery* 1959;45:531-534.
83. Meyer WH Jr, Starzl TE. The effect of Eck and reverse Eck fistula in dogs with experimental diabetes mellitus. *Surgery* 1959;45:760-764.
84. Hahn M, Massen O, Nencki M, Pawlow J. Die Eck'sche Fistel zwischen der unteren Holveue und der Pfortader and ihre Folgen fur den Organismus. *Arch Exp Pathol Pharmacol* 1893;32:161-210.
85. Starzl TE, Porter KA, Francavilla A. The Eck fistula in animals and humans. *Curr Probl Surg* 1983;20:687-752.

86. Goodrich EO Jr, Welch HF, Nelson JA, Beecher TS, Welch CS. Homotransplantation of the canine liver. *Surgery* 1956;39:244-251.
87. McBride RA, Wheeler HB, Smith LL, Moore FD, Dammin GJ. Homotransplantation of the canine liver as an orthotopic vascularized graft. Histologic and functional correlations during residence in the new host. *Am J Pathol* 1962;41:501-515.
88. Moore FD, Birtch AG, Dagher F, Veith F, Krisher JA, Order SE, et al. Immunosuppression and vascular insufficiency in liver transplantation. *Ann N Y Acad Sci* 1964;120:729-738.
89. Moore FD, ed. *Give and Take*. Philadelphia, PA: WB Saunders Co.; Garden City, NY: Doubleday and Co.; 1964.
90. Moore FD, ed. *A Miracle & A Privilege*. Washington, DC: Joseph Henry Press; 1995.
91. Merrill JP, Murray JE, Harrison JH, Friedman EA, Dealy JB Jr, Dammin GJ. Successful homotransplantation of the kidney between non-identical twins. *N Engl J Med* 1960;262:1251-1260.
92. Starzl TE, Kaupp HA Jr, Brock DR, Linman JW. Studies on the rejection of the transplanted homologous dog liver. *Surg Gynecol Obstet* 1961;112:135-144.
93. Burnet FM. The new approach to immunology. *N Engl J Med* 1961;264:24-34.
94. Starzl TE, Butz GW Jr, Brock DR, Linman JT, Moss WT. Canine liver homotransplants: The effect of host and graft irradiation. *Arch Surg* 1962;85:460-464.
95. Schwartz R, Stack J, Dameshek W. Effect of 6-mercaptopurine on antibody production. *Proc Soc Exp Biol Med* 1958;99:164-167.
96. Schwartz R, Dameshek W. Drug-induced immunological tolerance. *Nature* 1959;183:1682-1683.
97. Meeker W, Condie R, Weiner D, Varco RL, Good RA. Prolongation of skin homograft survival in rabbits by 6-mercaptopurine. *Proc Soc Exp Biol Med* 1959;102:459-461.
98. Schwartz R, Dameshek W. The effects of 6-mercaptopurine on homograft reactions. *J Clin Invest* 1960;39:952-958.
99. Zukoski CF, Lee HM, Hume DM. The prolongation of functional survival of canine renal homografts by 6-mercaptopurine. *Surg Forum* 1960;11:470-472.
100. Calne RY. The rejection of renal homografts: Inhibition in dogs by 6-

mercaptopurine. *Lancet* 1960;1:417-418.

101. Calne RY. Inhibition of the rejection of renal homografts in dogs by purine analogues. *Transplant Bull* 1961;28:445-461.

102. Calne RY, Alexandre GPJ, Murray JE. A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs. *Ann N Y Acad Sci* 1962;99:743-761.

103. Hamburger J, Vaysse J, Crosnier J, Tubiana M, Lalanne CM, Antoine B, et al. Transplantation of a kidney between nonmonozygotic twins after irradiation of the receiver. Good function at the fourth month. *Presse Med* 1959;67:1771-1775.

104. Hamburger J, Vaysse J, Crosnier J, Auvert J, Lalanne CL, Hopper J Jr. Renal homotransplantation in man after radiation of the recipient. *Am J Med* 1962;32:854-871.

105. Kuss R, Legrain M, Mathe G, Nedey R, Camey M. Homologous human kidney transplantation. Experience with six patients. *Postgrad Med J* 1962;38:528-531.

106. Murray JE, Merrill JP, Dammin GJ, Dealy JB Jr, Alexandre GW, Harrison JH. Kidney transplantation in modified recipients. *Ann Surg* 1962;156:337-355.

107. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. *N Engl J Med* 1963;268:1315-1323.

108. Starzl TE. History of clinical transplantation. *World J Surg* 2000;24:759-782. [reprinted as a chapter in: *Surgery: Basic Science and Clinical Evidence*. 2nd ed. JA Norton, PS Barie, RR Bollinger, AE Chang, SF Lowry, SJ Mulvihill, HI Pass, RW Thompson, eds. New York, NY: Springer; 2008:1681-1704.]

109. Starzl TE. Acquired immunologic tolerance: with particular reference to transplantation. *Immunol Res* 2007;38:6-41.

110. Starzl TE, Marchioro TL, Terasaki PI, Porter KA, Faris TD, Herrmann TJ, et al. Chronic survival after human renal homotransplantations: Lymphocyte-antigen matching, pathology and influence of thymectomy. *Ann Surg* 1965;162:749-787.

111. Starzl TE. *Experience in Renal Transplantation*. Philadelphia: W.B. Saunders Co.; 1964.

112. Starzl TE. Inaugural: presidential address, American Society of Transplant Surgeons. *Surgery* 1976;79:129-131.

113. Sicular A, Paronetto F, Kark AE, Dreiling DA, Burrows L, Popper H. Rejection of

the homotransplanted dog liver in the absence of hepatic insufficiency. *Proc Soc Exp Biol Med* 1963;112:760.

114. Demirleau J, Noureddine M, Vignes, Prawerman, Reziciner, Larraud, et al. Attempted hepatic homograft [in French]. *Mem Acad Chir (Paris)* 1964;90:177-179.

115. Picache RS, Kapur BML, Starzl TE. The effect of liver disease on the need for venous decompression during the anhepatic phase of canine orthotopic liver transplantation. *Surgery* 1970;67:319-321.

116. Marchioro TL, Porter KA, Dickinson TC, Faris TD, Starzl TE. Physiologic requirements for auxiliary liver homotransplantation. *Surg Gynecol Obstet* 1965;21:17-31.

117. Marchioro TL, Porter KA, Brown BI, Otte J-B, Starzl TE. The effect of partial portacaval transposition on the canine liver. *Surgery* 1967;61:723-732.

118. Starzl TE, Francavilla A, Halgrimson CG, Francavilla FR, Porter KA, Brown TH, et al. The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. *Surg Gynecol Obstet* 1973;137:179-199.

119. Starzl TE, Porter KA, Kashiwagi N, Lee IY, Russell WJI, Putnam CW. The effect of diabetes mellitus on portal blood hepatotrophic factors in dogs. *Surg Gynecol Obstet* 1975;140:549-562.

120. Starzl TE, Porter KA, Kashiwagi N, Putnam CW. Portal hepatotrophic factors, diabetes mellitus and acute liver atrophy, hypertrophy and regeneration. *Surg Gynecol Obstet* 1975;141:843-858.

121. Starzl TE, Lee IY, Porter KA, Putnam CW. The influence of portal blood upon lipid metabolism in normal and diabetic dogs and baboons. *Surg Gynecol Obstet* 1975;140:381-396.

122. Starzl TE, Francavilla A, Porter KA, Benichou J, Jones AF. The effect of splanchnic viscera removal upon canine liver regeneration. *Surg Gynecol Obstet* 1978;147:193-207.

123. Porter R, Whelan J, eds. *Hepatotrophic Factors (Ciba Foundation Symposium No. 55)*. Amsterdam: Elsevier/Excerpta Medica, North-Holland; 1978.

124. Francavilla A, Hagiya M, Porter KA, Polimeno L, Ihara I, Starzl TE. Augmenter of liver regeneration (ALR): its place in the universe of hepatic growth factors. *Hepatology* 1994;20:747-757.

125. Starzl TE, Marchioro TL, Sexton AW, Illingworth B, Waddell WR, Faris TD, et al. The effect of portacaval transposition on carbohydrate metabolism: Experimental and clinical observations. *Surgery* 1965;57:687-697.
126. Starzl TE, Putnam CW, Porter KA, Halgrimson CG, Corman J, Brown BI, et al. Portal diversion for the treatment of glycogen storage disease in humans. *Ann Surg* 1973;178:525-539.
127. Starzl TE, Chase HP, Ahrens EH Jr, McNamara DJ, Bilheimer DW, Schaefer EJ, et al. Portacaval shunt in patients with familial hypercholesterolemia. *Ann Surg* 1983;198:273-283.
128. Starzl TE. The little drummer girls. In: *The Puzzle People: Memoirs of a Transplant Surgeon*. Pittsburgh, PA: University of Pittsburgh Press; 1992:318-333 (annotation for Figure 5).
129. Starzl TE, Porter KA, Francavilla A, Iwatsuki S. Reversal of hepatic alpha-1-antitrypsin deposition after portacaval shunt. *Lancet* 1983;2:424-426.
130. Starzl TE, Porter KA, Busuttil RW, Pichlmayr R. Portacaval shunt in 3 children with alpha-1-antitrypsin deficiency: 9 to 12 - 1/3 years later. *Hepatology* 1990;11:152-154.
131. Brettschneider L, Daloze PM, Huguet C, Porter KA, Groth DG, Kashiwagi N, et al. The use of combined preservation techniques for extended storage of orthotopic liver homografts. *Surg Gynecol Obstet* 1968;126:263-274.
132. Starzl TE, Porter KA, Iwasaki Y, Marchioro TL, Kashiwagi N. The use of antilymphocyte globulin in human renal homotransplantation. In: Wolstenholme GEW, O'Connor M, eds. *Antilymphocytic Serum*. London: J&A Churchill Ltd.; 1967:4-34.
133. Calne RY, Williams R. Liver transplantation in man. I. Observations on technique and organization in five cases. *Br Med J* 1968;4:535-540.
134. Calne RY, Sells RA, Pena Jr, Davis DR, Millard PR, Herbertson BM, et al. Induction of immunological tolerance by porcine liver allografts. *Nature* 1969;223:472-474.
135. Barnard CN. What we have learned about heart transplants. *J Thorac Cardiovasc Surg* 1968;56:457-468.
136. Derom F, Barbier F, Ringoir S, Versieck J, Rolly G, Berzseny G, et al. Ten-month survival after lung homotransplantation in man. *J Thorac Cardiovasc Surg* 1971;61:835-

846.

137. Lillehei RC, Simmons RL, Najarian JS, Weil R, Uchida H, Ruiz JO, et al. Pancreaticoduodenal allotransplantation: Experimental and clinical observations. *Ann Surg* 1970;172:405-436.
138. Putnam CW, Porter KA, Peters RL, Ashcavai M, Redeker AG, Starzl TE. Liver replacement for alpha-1-antitrypsin deficiency. *Surgery* 1977;81:258-261.
139. Hood JM, Koep LJ, Peters RL, Schroter GPJ, Weil R III, Redeker AG, et al. Liver transplantation for advanced liver disease with alpha-1-antitrypsin deficiency. *N Engl J Med* 1980;302:272-275.
140. Malatack JJ, Finegold DN, Iwatsuki S, Shaw BW Jr, Gartner JC, Zitelli BJ, et al. Liver transplantation for type I glycogen storage disease. *Lancet* 1983;1:1073-1075.
141. Selby R, Starzl TE, Yunis E, Brown BI, Kendall RS, Tzakis A. Liver transplantation for Type IV glycogen storage disease. *N Engl J Med* 1991;324:39-42.
142. Starzl TE, Demetris AJ, Van Thiel DH. Medical progress: liver transplantation. Part I. *N Engl J Med* 1989;321:1014-1022; Part II. *N Engl J Med* 1989;321:1092-1099.
143. Starzl TE, Demetris AJ, Trucco M, Ricordi C, Ildstad S, Terasaki PI, et al. Chimerism after liver transplantation for type IV glycogen storage disease and Type I Gaucher's disease. *N Engl J Med* 1993;328:745-749.
144. Murase N, Demetris AJ, Woo J, Tanabe M, Furuya T, Todo S, et al. Graft versus host disease (GVHD) after BN to LEW compared to LEW to BN rat intestinal transplantation under FK 506. *Transplantation* 1993;55:1-7.
145. Demetris AJ, Murase N, Fujisaki S, Fung JJ, Rao AS, Starzl TE. Hematolymphoid cell trafficking, microchimerism, and GVHD reactions after liver, bone marrow, and heart transplantation. *Transplant Proc* 1993;25:3337-3344.
146. Murase N, Starzl TE, Tanabe M, Fujisaki S, Miyazawa H, Ye Q, et al. Variable chimerism, graft versus host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to Brown-Norway rats. *Transplantation* 1995;60:158-171.
147. Terakura M, Murase N, Demetris AJ, Ye Q, Thomson A, Starzl TE. Lymphoid/non-lymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. *Transplantation* 1998;66:350-357.

148. Sakamoto T, Ye Q, Lu L, Demetris AJ, Starzl TE, Murase N. Donor hematopoietic progenitor cells in non myeloablated rat recipients of allogeneic bone marrow and liver grafts. *Transplantation* 1999;67:833-840.
149. Ichikawa N, Demetris AJ, Starzl TE, Ye Q, Okuda T, Chun HJ, et al. Donor and recipient leukocytes in organ allografts of recipients with variable donor-specific tolerance: with particular reference to chronic rejection. *Liver Transpl* 2000;6:686-702.
150. Kiyomoto T, Toyokawa H, Nakao A, Kaizu T, Okuda T, Demetris AJ, et al. The difficulty of eliminating donor leukocyte microchimerism in rat recipients bearing established organ allografts. *Transplantation* 2006;81:438-444.
151. Qian S, Demetris AJ, Murase N, Rao AS, Fung JJ, Starzl TE. Murine liver allograft transplantation: Tolerance and donor cell chimerism. *Hepatology* 1994;19:916-924.
152. Lu L, Rudert WA, Qian S, McCaslin D, Fu F, Rao AS, et al. Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. *J Exp Med* 1995;182:379-387.
153. Qian S, Lu L, Fu F, Li Y, Starzl TE, Fung JJ, et al. Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. *J Immunol* 1997;158:4654-4661.
154. Lu L, Li W, Zhong C, Qian S, Fung JJ, Thomson AW, et al. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb. *Transplantation* 1999;68:747-757.
155. Starzl TE, Demetris AJ. Transplantation milestones: viewed with one- and two-way paradigms of tolerance. *JAMA* 1995;273:876-879.
156. Starzl TE, Demetris AJ, Murase N, Trucco M, Thomson AW, Rao AS. The lost chord: Microchimerism. *Immunol Today* 1996;17:577-584.
157. Murase N, Starzl TE, Ye Q, Tsamandas A, Thomson AW, Rao AS, et al. Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation: with particular reference to the liver. *Transplantation* 1996;61:1-4.

158. Taniguchi H, Toyoshima T, Fukao K, Nakauchi H. Presence of hematopoietic stem cells in the adult liver. *Nature Med* 1996;2:198-203.
159. Starzl TE, Murase N, Thomson A, Demetris AJ. Liver transplants contribute to their own success. *Nature Med* 1996;2:163-165.
160. Barker CF, Billingham RE. The role of afferent lymphatics in the rejection of skin homografts. *J Exp Med* 1968;128:197-221.
161. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic ignorance of vascularized organ transplants in the absence of secondary lymphoid tissue. *Nature Med* 2000;6:686-688.
162. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. *Cell* 1990;63:1249-1256.
163. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. *Nature* 1993;362:758-761.
164. Wood K, Sachs DH. Chimerism and transplantation tolerance: cause and effect. *Immunol Today* 1996;17:584.
165. Sykes M, Sachs DH. Mixed chimerism. *Philos Trans R Soc Lond B Biol Sci* 2001;356:707-726.
166. Zinkernagel RM, Doherty PC. The discovery of MHC restriction: The Road to Stockholm. *Immunol Today* 1997;18:14-17.
167. Zinkernagel RM, Moskophidis D, Kundig T, Oehen S, Pircher H, Hengartner H. Effector T-cell induction and T-cell memory versus peripheral deletion of T cells. *Immunol Rev* 1993;131:199-223.
168. Zinkernagel RM, Hengartner H. T-cell mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. *Immunol Today* 1994;15:262-268.
169. Zinkernagel RM. Immunology taught by viruses. *Science* 1996;271:173-178.
170. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localization regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. *Immunol Rev* 1997;156:199-209.
171. Ehl S, Aichele P, Ramseier H, Barchet W, Hombach J, Pircher H, et al. Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols

- for prevention of skin graft rejection. *Nat Med* 1998;4:1015-1019.
172. Bonilla WV, Geuking MB, Aichele P, Ludewig B, Hengartner H, Zinkernagel RM. Microchimerism maintains deletion of the donor cell-specific CD8⁺ T cell repertoire. *J Clin Invest* 2006;116:156-162.
173. Shapiro R, Ellis D, Tan HP, Moritz ML, Basu A, Vats AN, et al. Antilymphoid antibody preconditioning with tacrolimus monotherapy for pediatric renal transplantation. *J Pediatr* 2006;148:813-818.
174. Tan HP, Kaczorowski DJ, Basu A, Unruh M, McCauley J, Wu C, et al. Living donor renal transplantation using Alemtuzumab induction and tacrolimus monotherapy. *Am J Transplant* 2006;6:2409-2417.
175. McCurry K, Iacano A, Zeevi A, Yousem S, Girnita A, Husain S, et al. Early outcomes in human lung transplantation with thymoglobulin or campath-1H for recipient pretreatment followed by post-transplant tacrolimus near-monotherapy. *J Thorac Cardiovasc Surg* 2005;130:528-537.
176. Thai NL, Khan A, Tom K, Blisard D, Basu A, Tan HP, et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. *Transplantation*. 2006;82:1621-1624.
177. Abu-Elmagd K, Costa G, Bond GJ, Wu T, Murase N, Zeevi A, et al. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. *Transpl Int* 2009;22:96-109.
178. Abu-Elmagd K, Costa G, Bond GJ, Soltys K, Sindhi R, Wu T, et al. Five hundred intestinal and multivisceral transplantations at a single center. *Ann Surg* 2009;250:567-581.
179. Starzl TE, Lakkis FG. The unfinished legacy of liver transplantation: emphasis on immunology. *Hepatology* 2006;43:S151-S163.
180. Starzl TE, Hakala T, Tzakis A, Gordon R, Stieber A, Makowka L, et al. A multifactorial system for equitable selection of cadaveric kidney recipients. *JAMA* 1987;257:3073-3075.
181. Starzl TE, Gordon RD, Tzakis A, Staschak S, Fioravanti V, Broznick B, et al. Equitable allocation of extrarenal organs: With special reference to the liver. *Transplant*

Proc 1988;20:131-138.

182. Starzl TE, Shapiro R, Teperman L. The point system for organ distribution.

Transplant Proc 1989;21:3432-3436.

183. Horton R. Changing the US transplant System. Lancet 1998;351:352-379.

184. Eghtesad B, Bronsther O, Irish W, Casavilla A, Abu-Elmagd K, Van Thiel D, et al.

Disease gravity and urgency of need as guidelines for liver allocation. Hepatology

1994;20(Suppl. 1 Pt 2):56-62.

185. Bronsther O, Fung JJ, Tzakis A, Starzl TE. Prioritization and organ distribution for

liver transplantation. JAMA 1994;271:140-143; Bronsther O, Fung JJ, Tzakis A, Starzl

TE. The distribution of organs for liver transplantation. JAMA 1994;272:848-849.

186. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The

survival benefit of liver transplantation. Am J Transplant 2005;5:307-313.

187. Marsh JW, Gray E, Ness R, Starzl T. Complications of right lobe living donor liver

transplantation. J Hepatol 2009;51:715-724.

188. Clavien PA, Barkun J, deOliveria ML, Vauthey JN, Dindo D, Schulick RD. The

Clavien-Dindo classification of surgical complications: five year experience. Ann Surg

2009;250:187-196.

189. vanWyk J, Halgrimson CG, Giles G, Lilly J, Martineau G, Starzl TE. Liver

transplantation in biliary atresia with concomitant hepatoma. S Afr Med J 1972;46:885-

893. (annotation for Figure 7).

SUPPORTING APPENDICES

1. Supporting Appendix #1: The Neuroscience Interval

Item A: A 1991 letter written by the author (TES) in response to a request by Dr. Louise Marshall who was writing a history of the UCLA Brain Institute.

Item B: A related letter written in December 1951 from Professor H.W. Magoun to Dr. Alfred Blalock, supporting the candidacy of TES for a Johns Hopkins Internship. This letter was found by Dr. Henry T. Bahnson in 1989 when he was cleaning out his office

after retiring from the Surgical Chair at the University of Pittsburgh. Dr. Bahnson did not know who was responsible for the underlines, but thought that it probably was Dr. Blalock.

2. Supporting Appendix #2: Dust cover written by TES for the book, "*Defying the Gods*" by Scott McCartney (Macmillan Publishing Company, 1994) based on the program founded by Dr. Goran Klintmalm (a former fellow of Dr. Starzl) at Baylor University Hospital, Dallas.